The TRP-ECT supports the development and mechanistic understanding of safe and accessible next-generation engineered cell therapies for people with lupus through two types of studies: preclinical studies (up to $300,000 over two years) and ancillary studies to ongoing or completed clinical trials (up to $600,000 over two years).
2024 Funded Grants
-
Sensitive and Bispecific Chimeric TCR for SLE Therapy
Stanley Riddell, MD
Fred Hutchinson Cancer Center